Gene-gene interactions of CYP2A6 and MAOA polymorphisms on smoking behavior in Chinese male population

Pharmacogenetics and Genomics

Volumn 19, Issue 5, 2009, Pages 345-352

  Tang, Xun ^a,c   Guo, Song ^a,b   Sun, Hongqiang ^b   Song, Xuemei ^c   Jiang, Zuonin ^b   Sheng, Lixiang ^b   Zhou, Dongfeng ^a   Hu, Yonghua ^a,c   Chen, Dafang ^a,c  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Catechol O methyl transferase; Cytochrome P450 2A6; Dopamine beta hydroxylase; Genegene interaction; Monoamine oxidase A; Nicotine metabolism; Polymorphism; Smoking

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 2A6; DOPAMINE BETA MONOOXYGENASE; AMINE OXIDASE (FLAVIN CONTAINING); COUMARIN 7 HYDROXYLASE; COUMARIN 7-HYDROXYLASE; UNSPECIFIC MONOOXYGENASE;

ADULT; ARTICLE; CONTROLLED STUDY; GENE INTERACTION; GENE LOCUS; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HIGH RISK PATIENT; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SMOKING; AGED; BEHAVIOR; CHINA; GENETIC EPISTASIS; GENETIC LINKAGE; GENETICS; MIDDLE AGED; PHYSIOLOGY; POPULATION GENETICS;

NICOTIANA TABACUM;

ADULT; AGED; ARYL HYDROCARBON HYDROXYLASES; BEHAVIOR; CHINA; EPISTASIS, GENETIC; GENETICS, POPULATION; HUMANS; LINKAGE (GENETICS); MALE; MIDDLE AGED; MONOAMINE OXIDASE; POLYMORPHISM, GENETIC; SMOKING; YOUNG ADULT;

EID: 67149121209     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328329893c     Document Type: Article

References (33)

1. Wright AA, Katz IT. Tobacco tightrope-balancing disease prevention and economic development in China. N Engl J Med 2007; 356:1493-1496.
2. Munafo M, Clark T, Johnstone E, Murphy M, Walton R. The genetic basis for smoking behavior: a systematic review and meta-analysis. Nicotine Tob Res 2004; 6:583-597.
3. Ho MK, Tyndale RF. Overview of the pharmacogenomics of cigarette smoking. Pharmacogenomics J 2007; 7:81-98.
4. Benowitz NL, Perez-Stable EJ, Herrera B, Jacob P III. Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans. J Natl Cancer Inst 2002; 94:108-115.
5. Malaiyandi V, Sellers EM, Tyndale RF. Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clin Pharmacol Ther 2005; 77:145-158.
6. Nakajima M, Yokoi T. Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation. Drug Metab Pharmacokinet 2005; 20:227-235.
7. Carter B, Long T, Cinciripini P. A meta-analytic review of the CYP2A6 genotype and smoking behavior. Nicotine Tob Res 2004; 6:221-227.
8. Pontieri FE, Tanda G, Orzi F, Di Chiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 1996; 382:255-257.
9. McKinney EF, Walton RT, Yudkin P, Fuller A, Haldar NA, Mant D, et al. Association between polymorphisms in dopamine metabolic enzymes and tobacco consumption in smokers. Pharmacogenetics 2000; 10:483-491.
10. Jin Y, Chen D, Hu Y, Guo S, Sun H, Lu A, et al. Association between monoamine oxidase gene polymorphisms and smoking behaviour in Chinese males. Int J Neuropsychopharmacol 2006; 9:557-564.
11. Guo S, Chen DF, Zhou DF, Sun HQ, Wu GY, Haile CN, et al. Association of functional catechol O-methyl transferase (COMT) Val108Met polymorphism with smoking severity and age of smoking initiation in Chinese male smokers. Psychopharmacology 2007; 190:449-456.
12. Colilla S, Lerman C, Shields PG, Jepson C, Rukstalis M, Berlin J, et al. Association of catechol-O-methyltransferase with smoking cessation in two independent studies of women. Pharmacogenet Genomics 2005; 15:393-398.
13. Tochigi M, Suzuki K, Kato C, Otowa T, Hibino H, Umekage T, et al. Association study of monoamine oxidase and catechol-O-methyltransferase genes with smoking behavior. Pharmacogenet Genomics 2007; 17:867-872.
14. Collins FS, Guyer MS, Charkravarti A. Variations on a theme: cataloging human DNA sequence variation. Science 1997; 278:1580-1581.
15. Ritchie MD, Hahn LW, Roodi N, Bailey LR, Dupont WD, Parl FF, et al. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet 2001; 69:138-147.
16. Motsinger AA, Ritchie MD. Multifactor dimensionality reduction: an analysis strategy for modelling and detecting gene-gene interactions in human genetics and pharmacogenomics studies. Hum Genomics 2006; 2:318-328.
17. Niu T, Chen C, Ni J, Wang B, Fang Z, Shao H, et al. Nicotine dependence and its familial aggregation in Chinese. Int J Epidemiol 2000; 29:248-252.
18. Ariyoshi N, Takahashi Y, Miyamoto M, Umetsu Y, Daigo S, Tateishi T, et al. Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C. Pharmacogenetics 2000; 10:687-693.
19. Hsieh FY, Bloch DA, Larsen MD. A simple method of sample size calculation for linear and logistic regression. Stat Med 1998; 17:1623-1634.
20. Benowitz NL, Lessov-Schlaggar CN, Swan GE, Jacob P III. Female sex and oral contraceptive use accelerate nicotine metabolism. Clin Pharmacol Ther 2006; 79:480-488.
21. Oscarson M, McLellan RA, Gullsten H, Agundez JA, Benitez J, Rautio A, et al. Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. FEBS Lett 1999; 460:321-327.
22. Gambier N, Batt AM, Marie B, Pfister M, Siest G, Visvikis-Siest S. Association of CYP2A6*1B genetic variant with the amount of smoking in French adults from the Stanislas cohort. Pharmacogenomics J 2005; 5:271-275.
23. Oscarson M, McLellan RA, Gullsten H, Yue QY, Lang MA, Bernal ML, et al. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett 1999; 448:105-110.
24. Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, Tyndale RF. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 2004; 14: 615-626.
25. Nakajima M, Kwon JT, Tanaka N, Zenta T, Yamamoto Y, Yamamoto H, et al. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. Clin Pharmacol Ther 2001; 69:72-78.
26. Wang J, Pitarque M, Ingelman-Sundberg M. 30-UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression. Biochem Biophys Res Commun 2006; 340:491-497.
27. Johnstone EC, Clark TG, Griffiths SE, Murphy MF, Walton RT. Polymorphisms in dopamine metabolic enzymes and tobacco consumption in smokers: seeking confirmation of the association in a follow-up study. Pharmacogenetics 2002; 12:585-587.
28. Huang S, Cook DG, Hinks LJ, Chen XH, Ye S, Gilg JA, et al. CYP2A6, MAOA, DBH, DRD4, and 5HT2A genotypes, smoking behaviour and cotinine levels in 1518 UK adolescents. Pharmacogenet Genomics 2005; 15:839-850.
29. Sellers EM, Kaplan HL, Tyndale RF. Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clin Pharmacol Ther 2000; 68:35-43.
30. Zhang W, Kilicarslan T, Tyndale RF, Sellers EM. Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro. Drug Metab Dispos 2001; 29:897-902.
31. Sellers EM, Ramamoorthy Y, Zeman MV, Djordjevic MV, Tyndale RF. The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone (NNK) metabolism in vivo. Nicotine Tob Res 2003; 5:891-899.
32. Berlin I, Said S, Spreux-Varoquaux O, Launay JM, Olivares R, Millet V, et al. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clin Pharmacol Ther 1995; 58:444-452.
33. Guillem K, Vouillac C, Azar MR, Parsons LH, Koob GF, Cador M, et al. Monoamine oxidase A rather than monoamine oxidase B inhibition increases nicotine reinforcement in rats. Eur J Neurosci 2006; 24:3532-3540.